Search PubMed⌕ Search

Biomedical subjects

D Elia

Publications and source records attributed to D Elia.

At least 19 recordsLinked to original sources
PubMed2006

[Regression of Morton neuroma after local injection of steroids].

Morton neuroma is a non neoplastic lesion corresponding to perineural fibrosis encircling the common interdigital plantar nerve. Several therapeutic approaches are possible: conservative treatment or surgery. We report a case treated by local steroid injection where follow-up MR showed near complete regression of the lesion. Although local injection of steroid is a classical treatment, it is the first time to our knowledge that resolution or such a striking diminution of size is reported after infiltration.

Adrenal Cortex Hormones↗
PubMed2005

[Traumatic perinatal cervical dislocation].

We report on a case of cervical dislocation in which the severity of the lesion contrasts with the paucity of the symptoms. An eight-month-old girl presented with weakness of the left upper limb. She had a normal cephalic delivery. On the following days, increased weakness of the limb showed a spontaneous, partial regression. Clinical examination at eight months showed a normal physical and psychical development, a falling neck and an impossibility to maintain the sitting position, but a normal mobility of the lower limbs. Cervical radiography performed showed a complete dislocation. CT confirmed the diagnosis and eliminated congenital vertebral anomalies. Magnetic resonance imaging showed an important stretching and compression of the spinal cord. Cervical spine damage in the newborn are scarce and serious. The here reported case is characterized by a complete vertebral dislocation associated with medullar stretching and compression, but few initial symptoms.

Cervical Vertebrae↗
PubMed2005

[Couple, sexuality and sexual health].

Sexuality remained for a long time in the intimacy domain, judged worthy of a consultation reason only and yet as an illness cause or a male failure. Besides, dyspareunia and various women's illnesses took more time to be worthy of interest and care. And now it seems almost as if a turnaround were taking place. This mutation will probably induce some cultural changes. This paper focuses on the fifty-year-old man, in a world in which sexuality, from a universal right, becomes an obligation with the need for means and results, a requirement for performance. In order to discover how to approach these old problems with nowadays tools, we carried out a Medline review on sexuality and impotence, or erectile dysfunction (ED), which is a real problem in public health policy concerning more than 150 million men all over the world and more than 2 million in France. The analysis of the main papers associated with our own experience, allows us to better understand the changes in men/women relationship and the disclosure of male fragility, visible in the management of their well-being, their state of anxiety fowards this new women's control which probably influences their attitude in front of ageing and its consequences.

Attitude to Health↗
PubMed2005

[Erectile dysfunction drugs and women].

Erectile dysfunction (ED) is no more a taboo and the number of patients who are consulting a physician and asking for some help in this domain is growing every day. The quality of life of men presenting an ED and having access to treatments is continually improving. But what can be said concerning the partners' quality of life? Patients as much their partners clearly prefer lesser invasive therapeutics and the new oral drugs available present some advantages for the couples, and surely for a majority of female partners, willing to improve the spontaneity and the frequency of intercourse. It seems now obvious that the partner's help is one of the key points for a successful treatment. How will women facing this recovered virility react? What will they say in the secret of the consulting room? What could be exactly the role of the gynaecologist in assuming the female partner of a man treated for an ED? That is the object of the present article, dealing with quite an important matter.

Attitude↗
PubMed2004

[High frequency ultrasonography and celluscore: an improvement in the objective evaluation of cellulite phenomenon].

As they usually do not have any serious effect on health condition, cellulite phenomenons are not considered as potentially hazardous by general practitioners; unfortunately they involve almost all the feminine population after the forties and may really induce bad side effects either psychological or physical whatever the confusing origin of that cutaneous deformation: heredity, nutrition, circulatory and hormonal diseases etc. Trying to appreciate in a more scientific way this superficial skin disorder, we have developed a computerised questionnaire which can be combined with the finest upto date way of skin exploration, high frequency ultrasonography. It seems possible to consider now cellulite as the result of various disorders which can be separate into fibrotic or retentional phenomenons (surrounding superficial fat tissues) and the direct adipocyte reaction (adiposis). We hope to be able in the future to extend the treatment of cellulite beyond the limits of liposuction which seems until today the only way to bring some improvement to that phenomenon in spite of the very delicacy of the surgical approach.

Adipose Tissue↗
PubMed2000

Efficacy and tolerability of a low-dose of Oesclim (25 mcg daily) in the management of symptomatic menopausal women: a French open-label study.

OBJECTIVE: To establish the proportion of symptomatic postmenopausal women, whose HRT treatment is initiated on Oesclim 25, who can be satisfactorily maintained on this low dose after two months. STUDY DESIGN AND PATIENTS: This was an open-label, multicentre, non-comparative, four-month treatment study. Treatment was initiated with Oesclim 25 (17 beta-oestradiol transdermal patch, 25 mcg/day). Dosage could be increased to Oesclim 50 if required after two months, according to clinical evaluation. Sequential treatment with an oral progestagen was also given for > or = 12 days/month in all non-hysterectomised women. A total of 1465 women were included in the study. RESULTS: 82.3% (CI: 80.1-84.4) of patients remained on Oesclim 25 across the whole study. The mean number of hot flushes was reduced similarly by 93% and 94% at month 4 in the Oesclim 25 group and Oesclim 50 group, respectively. However, at month 2 the decrease in hot flushes and other menopausal symptoms was less marked until the dose was adjusted, in patients switching to Oesclim 50. In a global evaluation, 97.5% of the investigators and 95.7% of the patients rated the overall efficacy of the treatment as good/very good. Overall, treatment initiated at a low dose was well tolerated throughout the study, with a trend showing Oesclim 25 as being better tolerated than Oesclim 50. CONCLUSION: Oesclim low dose (25 mcg) can effectively reduce symptoms in most postmenopausal women with a very satisfactory level of tolerability. The risk/benefit ratio observed is probably one key reason for good patient compliance.

Administration, Cutaneous↗
PubMed1992

[Efficacy and acceptability of dexfenfluramine in women consulting in gynecology. 336 overweight patients treated for 3 months].

The efficacy on bodyweight and the acceptability of a three month treatment with dexfenfluramine (Isoméride), combined with a prescribed diet, were evaluated in 336 women followed by a gynecologist for overweight. These women were divided into three groups, those in the sexually active age group (80%) and perimenopausal and post-menopausal women (20%) and had the following characteristics: mean bodyweight 80.2 +/- 0.6 kg; excess bodyweight 35.0 +/- 0.5% of theoretical ideal weight, mean bodyweight index = 30.6 +/- 0.2 kg/m2. Simultaneously with the weight loss, a study of the change in gynecological symptoms was carried out at each consultation and for each group. Investigation of the bodyweight showed that 80% of the patient who followed the treatment for three months lost weight, the mean loss being 7.2 kg or 41.9% of the initial excess weight. Simultaneously with this loss of weight, there was an improvement in the gynecological symptoms in all three groups. These symptoms included those seen in the premenstrual phase (sexually active age group) and menopause-related symptoms in the perimenopausal and post menopausal groups. The acceptability and safety of Isomeride were also confirmed in this study.

Adult↗
PubMed1988

[Abortion induced by RU 486: importance of its combination with a prostaglandin derivative].

The antiprogesterone steroid RU 486 (17 beta-hydroxy-11 beta-(4-dimethylaminophenyl l)-17 alpha-(prop-1-ynyl) estra-4,9-dien-3-one), orally administered once (600 mg), is an efficient contragestive agent in approximately 80% of pregnant women who have been amenorrheic for up to 41 days. Later on, its use is not recommended since after 41 day of amenorrhea there is an increase in the number of incomplete expulsions. A vaginal suppository of 1 mg Gemeprost, a synthetic PG-E1 analogue, has been prescribed 36-48 hrs. after the administration of RU 486. Such a suppository cannot provoke the interruption of the pregnancy by itself. In 106 women seeking for the interruption of pregnancy, and who were amenorrheic for 49 days or less, RU 486 plus prostaglandin association led to the interruption of pregnancy in all cases, and no further instrumental intervention was required. This preliminary report suggests that this method is an efficient alternative to conventional techniques available presently.

Abortifacient Agents↗